3–12 day dispatch window due to updated U.S. documentation requirements • All tariff costs covered
Table of Contents
When it comes to botulinum toxin treatments, the choice is wide enough that many specialists simply return to the brand they know best. Botox has held that position for decades. Over the past ten years, though, Korean manufacturers have built a serious presence in the category, and Nabota from Daewoong Pharmaceutical is one of the products practitioners ask about most often.
Both products deliver botulinum toxin type A, and both do the same thing at the neuromuscular junction. The differences sit in the active substance, the regulatory record, the dosing characteristics and the price, and those are the points that decide which vial belongs in your fridge.
WORTH KNOWING
Both Botox and Nabota are intended for professional use only. You need a valid medical licence to order them, and FillerCloud verifies licence status before confirming an order.
Before comparing them in detail, it helps to set out what each product actually is. The two share a mechanism and a category, and differ in almost everything downstream of that.
Botox is a botulinum toxin type A product from Allergan, an AbbVie company. Its active substance, onabotulinumtoxinA, blocks acetylcholine release at the neuromuscular junction, producing a temporary reduction in targeted muscle activity. That mechanism underpins both its aesthetic use and an unusually long list of therapeutic indications.
In aesthetic practice, Botox is used for dynamic facial lines including glabellar lines, forehead lines and lateral canthal lines. Effects typically begin within several days of injection, with most patients noticing change during the first week and full effect developing over roughly two weeks depending on dose and area.
Nabota is manufactured by Daewoong Pharmaceutical in South Korea. Its active substance is prabotulinumtoxinA, which acts through the same mechanism: inhibition of acetylcholine release at motor nerve terminals. In the United States the same toxin is marketed as Jeuveau, approved by the FDA in February 2019 for moderate to severe glabellar lines, with two identical phase 3 studies behind that approval.
The product is supplied as a vacuum-dried powder in several vial strengths depending on market, commonly 50, 100 and 200 units, and contains human serum albumin and sodium chloride as excipients. It requires reconstitution with sterile saline before intramuscular administration.
WORTH KNOWING
Units are not interchangeable between botulinum toxin brands. A dose expressed in units of one product does not convert directly into units of another, so always follow the prescribing information for the specific product in hand.
| Feature | Botox | Nabota |
|---|---|---|
| Active substance | OnabotulinumtoxinA | PrabotulinumtoxinA |
| Manufacturer | Allergan (AbbVie) | Daewoong Pharmaceutical |
| US brand and approval | Botox, approved across many aesthetic and therapeutic indications | Jeuveau, FDA-approved February 2019 for glabellar lines |
| Presentation | Vacuum-dried powder, reconstituted before use | Vacuum-dried powder, reconstituted before use |
| Reported onset | Typically within several days | Described as marginally earlier in some reports |
| Duration in aesthetic use | Approximately three to four months | Approximately three to four months |
| Clinical track record | Decades of use across many indications | Newer, with phase 3 data in glabellar lines |
The similarities are substantial, which is why practitioners describe them as broadly comparable for aesthetic work:
Two identical phase 3 studies of prabotulinumtoxinA in glabellar lines reported efficacy and a safety profile consistent with the established botulinum toxin type A category, which is the evidence base behind its regulatory approval (Beer et al., Dermatologic Surgery, 2019).
The practical distinctions matter more than the similarities when you are choosing what to stock:
Repeated exposure to any botulinum toxin can generate neutralizing antibodies, and secondary non-response is a recognised phenomenon across the whole category rather than a property of one brand. Protein load, cumulative dose and treatment interval are the factors usually discussed in that context, and the practical controls are the same regardless of product: appropriate dosing and adequate intervals between sessions.
Marketing claims about purity should be read with that in mind. Manufacturing processes differ, but the clinically meaningful question is whether a given patient develops reduced response over time, and that is managed through protocol rather than product choice alone.
For routine aesthetic work on dynamic facial lines, both products do the job, and the decision usually comes down to cost, familiarity and what the patient expects to hear. Botox suits practices where brand recognition matters to patients or where therapeutic indications are part of the workload. Nabota suits practices looking for a cost-effective toxin with phase 3 data behind it for aesthetic indications.
If you are weighing several Korean toxins rather than only these two, our comparisons of Botox vs Innotox and Xeomin vs Innotox cover the neighbouring options, and the Innotox dosage chart shows how unit differences play out in practice.
WORTH KNOWING
Neither product is a substitute for the other in a treatment plan already under way. Switching brands mid-course means re-establishing the dose for that patient rather than transferring units across.
Licensed specialists can order Nabota (Jeuveau) 100U and Botox from FillerCloud, with licence verification before dispatch and temperature-controlled shipping on every order.
Yes. Botox contains onabotulinumtoxinA and Nabota contains prabotulinumtoxinA, and both are botulinum toxin type A preparations derived from Clostridium botulinum. Both block acetylcholine release at the neuromuscular junction to reduce targeted muscle activity temporarily.
The same toxin is marketed in the United States as Jeuveau, approved by the FDA in February 2019 for moderate to severe glabellar lines in adults. That approval covers one aesthetic indication, while Botox holds a much broader list of aesthetic and therapeutic indications.
No. Unit potency is defined per product, so a dose in units of one toxin does not convert directly into units of another. Dosing should follow the prescribing information for the specific product being used, and switching brands mid-course means re-establishing the dose for that patient.
Aesthetic results with both products generally persist around three to four months, with full effect developing over roughly two weeks after injection. Duration varies with dose, treatment area, muscle mass and individual response rather than differing systematically between the two brands.
For routine work on dynamic facial lines both are viable, so the decision usually rests on cost, familiarity and patient expectations. Botox suits practices where brand recognition or therapeutic indications matter; Nabota suits those seeking a lower-cost toxin with phase 3 data behind its aesthetic indication.
You may download the form, complete it and email back to [email protected].
Or fax it at 360.768.3126
